Since activation of VEGFR2 by VEGF is regarded as the most critical driver of tumor angiogenesis, inhibition of the VEGF/VEGFR2 axis by antibodies or decoy receptors capturing VEGF, antibodies blocking VEGFR2 or tyrosine kinase inhibitors inhibiting downstream signaling of VEGFR2, respectively, have been extensively investigated as anti-angiogenic therapeutic strategies [10,13,14]. The gene discussed is VEGFA; the disease is neoplasm.